|Positive WB detected in||MDA-MB-453s cells, HEK-293 cells, U2OS cells, HeLa cells, mouse testis tissue, rat testis tissue|
|Positive IHC detected in||human prostate cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
The immunogen of 10305-1-AP is PLK1 Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||PLK1 fusion protein Ag0284|
|Full Name||polo-like kinase 1 (Drosophila)|
|Calculated molecular weight||68 kDa|
|Observed molecular weight||62 kDa|
|GenBank accession number||BC002369|
|Gene ID (NCBI)||5347|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
PLK1(Polo-like kinase 1), also named as PLK and STPK13, belongs to the protein kinase superfamily, Ser/Thr protein kinase family and CDC5/Polo subfamily. PLK1 is a Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of APC/C inhibitors, and the regulation of mitotic exit and cytokinesis.The localization of Polo changes during the cell cycle. In interphase, Polo shows a mostly diffuse cytoplasmic localization. Polo becomes concentrated on centrosomes from early prophase and appears on centromeres or kinetochores from late prophase, before nuclear envelope breakdown (NEB). After anaphase onset, Polo relocalizes to the central spindle and remains enriched at the midbody ring in late stages of cytokinesis (PMID: 29167465).
Translation control of the immune checkpoint in cancer and its therapeutic targeting.
ACS Biomater Sci Eng
Stimuli-Responsive and Highly Penetrable Nanoparticles as a Multifunctional Nanoplatform for Boosting Nonsmall Cell Lung Cancer siRNA Therapy.
CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
Aging (Albany NY)
PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation.
Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition.
Int J Nanomedicine
pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.